Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa

Simple item page
dc.contributor.authorBrado, Dominiken_ZA
dc.contributor.authorObasa, Adetayo Emmanuelen_ZA
dc.contributor.authorIkomey, George Mondindeen_ZA
dc.contributor.authorCloete, Rubenen_ZA
dc.contributor.authorSingh, Kamalendraen_ZA
dc.contributor.authorEngelbrecht, Susanen_ZA
dc.contributor.authorNeogi, Ujjwalen_ZA
dc.contributor.authorJacobs, Graeme Brendonen_ZA
dc.date.accessioned2018-04-24T12:38:58Z
dc.date.available2018-04-24T12:38:58Z
dc.date.issued2018
dc.descriptionCITATION: Brado, D., et al. 2018. Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa. Scientific Reports, 8:4709, doi:10.1038/s41598-018-22914-5.
dc.descriptionThe original publication is available at https://www.nature.com
dc.descriptionPublication of this article was funded by the Stellenbosch University Open Access Fund.
dc.description.abstractENGLISH ABSTRACT: HIV-Integrase (IN) has proven to be a viable target for highly specific HIV-1 therapy. We aimed to characterize the HIV-1 IN gene in a South African context and identify resistance-associated mutations (RAMs) against available first and second generation Integrase strand-transfer inhibitors (InSTIs). We performed genetic analyses on 91 treatment-naïve HIV-1 infected patients, as well as 314 treatment-naive South African HIV-1 IN-sequences, downloaded from Los Alamos HIV Sequence Database. Genotypic analyses revealed the absence of major RAMs in the cohort collected before the broad availability of combination antiretroviral therapy (cART) and INSTI in South Africa, however, occurred at a rate of 2.85% (9/314) in database derived sequences. RAMs were present at IN-positions 66, 92, 143, 147 and 148, all of which may confer resistance to Raltegravir (RAL) and Elvitegravir (EVG), but are unlikely to affect second-generation Dolutegravir (DTG), except mutations in the Q148 pathway. Furthermore, protein modeling showed, naturally occurring polymorphisms impact the stability of the intasome-complex and therefore may contribute to an overall potency against InSTIs. Our data suggest the prevalence of InSTI RAMs, against InSTIs, is low in South Africa, but natural polymorphisms and subtype-specific differences may influence the effect of individual treatment regimens.en_ZA
dc.description.urihttps://www.nature.com/articles/s41598-018-22914-5
dc.description.versionPublisher's version
dc.format.extent9 pages : illustrationsen_ZA
dc.identifier.citationBrado, D., et al. 2018. Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa. Scientific Reports, 8:4709, doi:10.1038/s41598-018-22914-5
dc.identifier.issn2045-2322 (online)
dc.identifier.otherdoi:10.1038/s41598-018-22914-5
dc.identifier.urihttp://hdl.handle.net/10019.1/103973
dc.language.isoen_ZAen_ZA
dc.publisherNature Publishing Groupen_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectHIV-integraseen_ZA
dc.subjectHIV -- Treatmenten_ZA
dc.subjectAntiretroviral agentsen_ZA
dc.subjectResistance to drugsen_ZA
dc.subjectINH (Drug)en_ZA
dc.titleAnalyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africaen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
brado_analyses_2018.pdf
Size:
2.42 MB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Medical Virology)